Image Analysis Group (IAG) and Takeda Pharmaceutical Company have extended their partnership to bring an AI-powered histopathology image analysis tool to clinics.

We recognize the importance of collaborations with digital health leaders, such as IAG, to identify and pursue breakthrough technologies to advance patient care. »

— Dr. Adsul, Takeda Pharmaceuticals International AG

PHILADELPHIA, PENNSYLVANIA, USA, Feb. 1, 2022 / — IAG, Image Analysis Group, the expert imaging company and a technology leader in clinical research, today announced that it has extended its collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) for a novel AI-powered histopathology image analysis tool for ulcerative colitis (UC). The collaborators plan to introduce the new AI tool to clinics after the success of its first phase of research.

This collaboration is supported by leading clinical centers and thought leaders, including sites in Switzerland, Canada, the United States, Israel and Portugal.
The companies have been working together since 2019 and have developed a new method based on artificial intelligence (AI) for the evaluation of histopathological images of ulcerative colitis. The tool will potentially enable practicing gastroenterologists to assess disease activity with an accurate, reproducible and reliable automated method in patients with UC. To date, the AI ​​tool has been trained and tested on 200 images, showing performance comparable to that of a human expert. In the next step, the partners will engage eight world-renowned sites, which will test the AI ​​tool in their clinical practices.

“Together with our business and academic partners, we are excited to be able to advance clinical decision-making by bringing better technologies to the game,” said Dr. Olga Kubassova, CEO of IAG, Image Analysis Group.

“Improving clinical decision-making with AI in the field of histopathology has the potential to bring great value to the management of patients with ulcerative colitis. The ability of our AI tool to provide additional information about disease status and patient response to a new treatment in real time gives us the ability to gain more insights and make better and better decisions. faster,” said Professor Laurant Peyrin-Biroulet, from the Department of Hepato-Gastroenterology and Inserm U954, Nancy University Hospital.

“As part of our 30-year commitment to gastroenterology, we recognize the importance of collaborations with digital health leaders, such as IAG, to identify and pursue breakthrough technologies to advance patient care. patients. We see great potential in this initiative and are excited to enter the next phase of research using deep learning models and AI to support gastroenterologists in their patient care,” said Dr. Shashi Adsul, Senior Director, Head of Global Medical Unit at Takeda Pharmaceuticals International SA.

About IAG, Image Analysis Group

IAG, Image Analysis Group is a one-stop partner for life science companies, leading in AI-based drug development and precision medicine. IAG leverages its expertise in medical imaging and the power of Dynamika™, our proprietary cloud-based platform, to reduce clinical development risk and get lifesaving treatments into the hands of patients much earlier. IAG provides early assessments of drug efficacy, intelligent patient recruitment, and predictive analysis of advanced treatment manifestations, reducing investment risk and accelerating study results. IAG bio-partnering takes a broader view of asset development by providing R&D solutions, operational scope, radiological expertise through risk-sharing financing and partnership models. For more information, visit


About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader, headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided through our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: oncology, rare genetics and hematology, neurosciences and gastroenterology (GI). We also make targeted R&D investments in plasma-derived therapies and vaccines. We are focused on developing highly innovative medicines that help make a difference in people’s lives by pushing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust pipeline and diversified in terms of modalities. Our employees are committed to improving the quality of life of patients and working with our healthcare partners in approximately 80 countries and regions. For more information, visit

Rose Palone
IAG, Image Analysis Group
+1 267-857-8638
write to us here